
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson is attractive because the 2023 consumer separation sharpened its focus on higher-return Innovative Medicines and MedTech, improving productivity and supporting stronger margins. Its core drug franchises in immunology, oncology, and neurology are showing durable momentum, with Tremfya, Darzalex, Icotyde, and Spravato offsetting pressure from certain headwinds and sustaining volume growth. The company also has a robust pipeline and a broad MedTech platform, with 12 platforms above $1B in sales and leadership in 11 of them, while just over half of revenue comes from the United States.
Bears say
Johnson & Johnson is vulnerable to slower organic revenue growth as loss of exclusivity pressures key drugs such as Stelara, with biosimilar erosion already in its year two and full-year erosion guidance of about 60% still intact. Its innovative medicine pipeline may not offset that drag if products like Tremfya, Carvykti, Rybrevant, the TARIS platform, nipocalimab, and milvexian fail to gain traction, while MedTech faces persistent competitive headwinds in electrophysiology and pulsed field ablation that could delay a 2H26 recovery. Added uncertainty from M&A integration risk, weaker P&L discipline, U.S. drug pricing reform, and ongoing talc litigation supports a cautious view on earnings durability and valuation.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Johnson & Johnson (JNJ) Forecast
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares